CN111344006A - 细胞 - Google Patents

细胞 Download PDF

Info

Publication number
CN111344006A
CN111344006A CN201880073185.5A CN201880073185A CN111344006A CN 111344006 A CN111344006 A CN 111344006A CN 201880073185 A CN201880073185 A CN 201880073185A CN 111344006 A CN111344006 A CN 111344006A
Authority
CN
China
Prior art keywords
leu
ala
gly
arg
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073185.5A
Other languages
English (en)
Chinese (zh)
Inventor
S.托马斯
M.普莱
P.史密斯
I.甘农
W.巴兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of CN111344006A publication Critical patent/CN111344006A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN201880073185.5A 2017-11-13 2018-11-12 细胞 Pending CN111344006A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1718697.4A GB201718697D0 (en) 2017-11-13 2017-11-13 Cell
GB1718697.4 2017-11-13
PCT/GB2018/053262 WO2019092442A1 (en) 2017-11-13 2018-11-12 Cell

Publications (1)

Publication Number Publication Date
CN111344006A true CN111344006A (zh) 2020-06-26

Family

ID=60788303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073185.5A Pending CN111344006A (zh) 2017-11-13 2018-11-12 细胞

Country Status (8)

Country Link
US (1) US20200345776A1 (https=)
EP (1) EP3710045A1 (https=)
JP (1) JP2021502102A (https=)
CN (1) CN111344006A (https=)
AU (1) AU2018364490A1 (https=)
CA (1) CA3082265A1 (https=)
GB (1) GB201718697D0 (https=)
WO (1) WO2019092442A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463362A (zh) * 2023-06-15 2023-07-21 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CN117043180A (zh) * 2020-09-11 2023-11-10 新加坡国立大学 用于器官移植患者的免疫疗法的免疫抑制剂药物抗性装甲tcr t细胞
CN117384931B (zh) * 2023-12-06 2024-03-08 中国中医科学院中药研究所 一种GSK-3β抑制剂的制备方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COEXPRESSED CATALASE PROTECTS CHIMERIC ANTIGEN RECEPTOR-REDIRECT: "Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity", 《J IMMUNOL》 *
FREDERICK L LOCKE等: "Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma", 《MOL THER》 *
JOANNA BRUNKER等: "Photoacoustic imaging using genetically encoded reporters: a review", 《J BIOMED OPT》 *
MONICA CASUCCI PHD等: "Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication", 《BLOOD》 *
RACHAEL MOONEY等: "Cell-mediated enzyme prodrug cancer therapies", 《ADV DRUG DELIV REV》 *
SEONG YEOL CHOI等: "Violacein: Properties and Production of a Versatile Bacterial Pigment", 《BIOMED RES INT》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116463362A (zh) * 2023-06-15 2023-07-21 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法
CN116463362B (zh) * 2023-06-15 2023-09-19 中国中医科学院中药研究所 一种细胞分裂抑制剂的制备方法

Also Published As

Publication number Publication date
US20200345776A1 (en) 2020-11-05
AU2018364490A1 (en) 2020-05-21
GB201718697D0 (en) 2017-12-27
EP3710045A1 (en) 2020-09-23
WO2019092442A1 (en) 2019-05-16
JP2021502102A (ja) 2021-01-28
CA3082265A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
US12534536B2 (en) Natural killer cells expressing a chimeric antigen receptor that binds CD38
CN104780939B (zh) 用于细胞免疫治疗的方法和组合物
JP2022064952A (ja) キメラ抗原受容体およびその使用方法
CN111344006A (zh) 细胞
CN112204133B (zh) Car nk细胞
KR20190133732A (ko) 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
KR102333377B1 (ko) 키메라 항원 수용체
CN107106670A (zh) 用于修饰的t细胞的方法和组合物
CN117177760A (zh) 用于受控和特异性car t细胞活性的嵌合抗原受体（car）信号传导分子
KR20170093248A (ko) 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법
CN114514247A (zh) Car-cd123载体及其用途
CN111954813B (zh) 工程化细胞溶解性免疫细胞
CN117412984A (zh) 通过使用近端信号传导分子增强t细胞功能
JP7054181B2 (ja) キメラ抗原受容体
HK40081199A (en) Engineered natural killer cells and uses thereof
HK40061900A (en) Engineered natural killer cells and uses thereof
HK40061900B (en) Engineered natural killer cells and uses thereof
HK40018917A (en) Engineered natural killer cells and uses thereof
HK40018917B (en) Engineered natural killer cells and uses thereof
HK40036126B (zh) Car nk细胞
HK1262291A1 (en) Engineered natural killer cells and uses thereof
HK1262291B (en) Engineered natural killer cells and uses thereof
NZ757552B2 (en) Chimeric antigen receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200626

WD01 Invention patent application deemed withdrawn after publication